Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen

被引：0
作者：
Davies, C [1 ]
机构：
[1] Univ Oxford, Studies Unit, Clin Trial Serv & Epidemiol, Oxford, England
来源：
CANCER TREATMENT REVIEWS | 2004年 / 30卷 / 06期
关键词：
D O I：
10.1016/j.ctrv.2004.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：583 / 588
页数：6
相关论文
共 22 条
  • [1] ABE O, 1992, LANCET, V339, P71
  • [2] [Anonymous], 2000, NIH Consens Statement, V17, P1
  • [3] [Anonymous], 1988, NEW ENGL J MED, V319, P1681
  • [4] [Anonymous], 1992, Lancet, V339, P1
  • [5] [Anonymous], 1990, TREATM EARL BREAST C
  • [6] Baum M, 2002, LANCET, V359, P2131
  • [7] Baum M, 2003, Cancer, V98, P1802
  • [8] SUDDEN FALL IN BREAST-CANCER DEATH RATES IN ENGLAND AND WALES
    BERAL, V
    HERMON, C
    REEVES, G
    PETO, R
    [J]. LANCET, 1995, 345 (8965): : 1642 - 1643
  • [9] Boccardo F, 2003, BREAST CANCER RES TR, V82, pS6
  • [10] Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study
    Boccardo, F
    Rubagotti, A
    Amoroso, D
    Mesiti, M
    Romeo, D
    Caroti, C
    Farris, A
    Cruciani, G
    Villa, E
    Schieppati, G
    Mustacchi, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) : 4209 - 4215
123